FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027409329> ?p ?o ?g. }

• W2027409329 endingPage "795" @default.
• W2027409329 startingPage "790" @default.
• W2027409329 abstract "Approximately 20% of patients with colorectal cancer die of metastases confined to the liver. A meta-analysis recently performed by our group confirmed that in these patients hepatic arterial infusion of 5-fluoro-2'-deoxyuridine, compared with intravenous chemotherapy with fluoropyrimidines or supportive care (including symptom palliation when necessary), improved tumor response.Because of the high cost of hepatic arterial infusion, we undertook a cost-effectiveness analysis that related the cost of such therapy to its medical efficacy.The patient population was drawn from the seven randomized clinical trials included in the meta-analysis and included individual data on 654 patients. Of these seven trials, five compared hepatic arterial infusion and intravenous chemotherapy and two compared hepatic arterial infusion and a control group in which some patients could be left untreated. Patients assigned to receive hepatic arterial infusion made up the hepatic arterial infusion group; the other patients constituted the control group. The measures of efficacy were survival and tumor response. Health-care costs (in 1995 U.S. dollars) were computed over the duration of patient follow-up and were derived from actual costs in two centers, one at Henri Mondor Hospital (Paris, France) and the other at Stanford University Medical Center (Palo Alto, CA). The total cost of treatment included the initial procedure, chemotherapy cycles, and main complications.The mean gain in life expectancy in the hepatic arterial infusion group compared with the control group was 3.2 months (standard error = 1.0 month). For patients treated by hepatic arterial infusion in Paris, the hepatic arterial infusion pump, initial hospitalization, and the entire process (including follow-up and complications) cost, on average, $8400, $15172, and $29562, respectively; in Palo Alto, these costs were $4700, $13784, and $25 208, respectively. For patients in the control groups in Paris and Palo Alto, the total treatment costs were, on average, $9926 and $5928. The additional costs of hepatic arterial infusion over control treatment were $19636 in Paris and $19280 in Palo Alto. The cost-effectiveness (i.e., the additional cost divided by the additional benefit) with respect to survival of the patients in the hepatic arterial infusion group compared with the patients in the control group was $73635 per life-year in Paris and $72300 per life-year in Palo Alto.The cost-effectiveness of localized chemotherapy for colorectal liver metastases is within the range of accepted treatments for serious medical conditions, although it might be considered borderline by policy-makers in some countries. Prospective clinical trials should be conducted to more definitively answer this question." @default.
• W2027409329 created "2016-06-24" @default.
• W2027409329 creator A5004046244 @default.
• W2027409329 creator A5011163683 @default.
• W2027409329 creator A5011608816 @default.
• W2027409329 creator A5012365132 @default.
• W2027409329 creator A5012784092 @default.
• W2027409329 creator A5051044981 @default.
• W2027409329 creator A5051083388 @default.
• W2027409329 creator A5061209536 @default.
• W2027409329 creator A5065617907 @default.
• W2027409329 creator A5068430888 @default.
• W2027409329 creator A5070839021 @default.
• W2027409329 creator A5080054249 @default.
• W2027409329 creator A5085474533 @default.
• W2027409329 date "1997-06-04" @default.
• W2027409329 modified "2023-09-25" @default.
• W2027409329 title "Economic Implications of Hepatic Arterial Infusion Chemotherapy in Treatment of Nonresectable Colorectal Liver Metastases" @default.
• W2027409329 cites W1835268604 @default.
• W2027409329 cites W1930945683 @default.
• W2027409329 cites W1969825132 @default.
• W2027409329 cites W1992025567 @default.
• W2027409329 cites W1997692902 @default.
• W2027409329 cites W2007615142 @default.
• W2027409329 cites W2016751107 @default.
• W2027409329 cites W2018938338 @default.
• W2027409329 cites W2024514655 @default.
• W2027409329 cites W2039280807 @default.
• W2027409329 cites W2044224410 @default.
• W2027409329 cites W2058352743 @default.
• W2027409329 cites W2068732984 @default.
• W2027409329 cites W2083415882 @default.
• W2027409329 cites W2122364701 @default.
• W2027409329 cites W2128813634 @default.
• W2027409329 cites W2160410432 @default.
• W2027409329 cites W2163587713 @default.
• W2027409329 cites W2319969471 @default.
• W2027409329 cites W2414022851 @default.
• W2027409329 cites W2468837473 @default.
• W2027409329 cites W2593286047 @default.
• W2027409329 cites W2602544133 @default.
• W2027409329 cites W4238668552 @default.
• W2027409329 cites W4246299175 @default.
• W2027409329 doi "https://doi.org/10.1093/jnci/89.11.790" @default.
• W2027409329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9182977" @default.
• W2027409329 hasPublicationYear "1997" @default.
• W2027409329 type Work @default.
• W2027409329 sameAs 2027409329 @default.
• W2027409329 citedByCount "46" @default.
• W2027409329 countsByYear W20274093292016 @default.
• W2027409329 countsByYear W20274093292023 @default.
• W2027409329 crossrefType "journal-article" @default.
• W2027409329 hasAuthorship W2027409329A5004046244 @default.
• W2027409329 hasAuthorship W2027409329A5011163683 @default.
• W2027409329 hasAuthorship W2027409329A5011608816 @default.
• W2027409329 hasAuthorship W2027409329A5012365132 @default.
• W2027409329 hasAuthorship W2027409329A5012784092 @default.
• W2027409329 hasAuthorship W2027409329A5051044981 @default.
• W2027409329 hasAuthorship W2027409329A5051083388 @default.
• W2027409329 hasAuthorship W2027409329A5061209536 @default.
• W2027409329 hasAuthorship W2027409329A5065617907 @default.
• W2027409329 hasAuthorship W2027409329A5068430888 @default.
• W2027409329 hasAuthorship W2027409329A5070839021 @default.
• W2027409329 hasAuthorship W2027409329A5080054249 @default.
• W2027409329 hasAuthorship W2027409329A5085474533 @default.
• W2027409329 hasConcept C121608353 @default.
• W2027409329 hasConcept C126322002 @default.
• W2027409329 hasConcept C141071460 @default.
• W2027409329 hasConcept C168563851 @default.
• W2027409329 hasConcept C2776694085 @default.
• W2027409329 hasConcept C2778405590 @default.
• W2027409329 hasConcept C2779352459 @default.
• W2027409329 hasConcept C2908647359 @default.
• W2027409329 hasConcept C526805850 @default.
• W2027409329 hasConcept C535046627 @default.
• W2027409329 hasConcept C71924100 @default.
• W2027409329 hasConcept C99454951 @default.
• W2027409329 hasConceptScore W2027409329C121608353 @default.
• W2027409329 hasConceptScore W2027409329C126322002 @default.
• W2027409329 hasConceptScore W2027409329C141071460 @default.
• W2027409329 hasConceptScore W2027409329C168563851 @default.
• W2027409329 hasConceptScore W2027409329C2776694085 @default.
• W2027409329 hasConceptScore W2027409329C2778405590 @default.
• W2027409329 hasConceptScore W2027409329C2779352459 @default.
• W2027409329 hasConceptScore W2027409329C2908647359 @default.
• W2027409329 hasConceptScore W2027409329C526805850 @default.
• W2027409329 hasConceptScore W2027409329C535046627 @default.
• W2027409329 hasConceptScore W2027409329C71924100 @default.
• W2027409329 hasConceptScore W2027409329C99454951 @default.
• W2027409329 hasIssue "11" @default.
• W2027409329 hasLocation W20274093291 @default.
• W2027409329 hasLocation W20274093292 @default.
• W2027409329 hasOpenAccess W2027409329 @default.
• W2027409329 hasPrimaryLocation W20274093291 @default.
• W2027409329 hasRelatedWork W2052465278 @default.
• W2027409329 hasRelatedWork W2370852907 @default.
• W2027409329 hasRelatedWork W2411523114 @default.
• W2027409329 hasRelatedWork W2415133316 @default.

• next